66.21 -0.30 (-0.45%)
Pre-market: 7:55AM EDT
|Mr. Daniel P. O'Day||Chairman & CEO||7.48M||N/A||1964|
|Mr. Andrew D. Dickinson||Exec. VP & CFO||2.71M||N/A||1970|
|Mr. Brett A. Pletcher||Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.||2.71M||1.06M||1968|
|Ms. Johanna Mercier||Chief Commercial Officer||4.86M||N/A||1970|
|Dr. Merdad V. Parsey M.D., Ph.D.||Chief Medical Officer||3.85M||N/A||1963|
|Ms. Diane E. Wilfong||Sr. VP, Corp. Controller & Chief Accounting Officer||N/A||N/A||1962|
|Ms. Jacquie Ross C.F.A.||VP of Investor Relations||N/A||N/A||N/A|
|Ms. Jyoti K. Mehra||Exec. VP of HR||N/A||N/A||N/A|
|Dr. Taiyin Yang||Exec. VP of Pharmaceutical Devel. & Manufacturing||N/A||N/A||1954|
|Dr. Diana M. Brainard M.D.||Sr. VP of HIV & Emerging Viral Infections||N/A||N/A||1971|
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences, Inc.’s ISS governance QualityScore as of 30 April 2021 is 4. The pillar scores are Audit: 1; Board: 2; Shareholder rights: 2; Compensation: 9.